{"id":"NCT00903409","sponsor":"GlaxoSmithKline","briefTitle":"Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Lovaza® and Simvastatin Therapy in Hypertriglyceridemic Subjects","officialTitle":"OM6X: An Open-Label Extension of a Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Combined Lovaza (Previously Omacor®) and Simvastatin Therapy in Hypertriglyceridemic Subjects","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-11-15","primaryCompletion":"2008-06-27","completion":"2008-06-27","firstPosted":"2009-05-18","resultsPosted":"2009-08-04","lastUpdate":"2017-10-09"},"enrollment":188,"design":{"allocation":"RANDOMIZED","model":"SINGLE_GROUP","masking":null,"primaryPurpose":"TREATMENT"},"conditions":["Hypertriglyceridemia"],"interventions":[{"type":"DRUG","name":"Simvastatin + Lovaza® (omega-3-acid ethyl esters)","otherNames":[]}],"arms":[{"label":"Simvastatin + Lovaza® (\"Non-switchers\")","type":"EXPERIMENTAL"},{"label":"Simvastatin + Lovaza® (\"Switchers\")","type":"EXPERIMENTAL"}],"summary":"In a previous trial (LOV111858/OM6), subjects received in a double-blind fashion either 4 g/day of Lovaza® (omega-3-ethyl esters) \\[formerly known as Omacor\\] co-administered with simvastatin 40 mg/day or placebo co-administered with simvastatin 40 mg/day for 8 weeks. This extension trial, LOV111818/OM6X assessed the continued efficacy and safety of Lovaza® (omega-3-ethyl esters) co-administered with simvastatin 40 mg vs. switching from simvastatin plus placebo to simvastatin plus Lovaza® for lowering non-High Density Lipoprotein-Cholesterol (non-HDL-C) levels at 4 months (primary endpoint) and additionally at 12 and 24 months.","primaryOutcome":{"measure":"Median Percent Change of Non-HDL-C (High Density Lipoprotein-Cholesterol) in Switchers vs. Non-Switchers Subjects From LOV111858 End-of-Treatment (Week 8) to Month 4 of Extension Study (LOV111818)","timeFrame":"Month 4 (LOV111818)","effectByArm":[{"arm":"Non-switcher","deltaMin":0.9,"sd":null},{"arm":"Switcher","deltaMin":-9.4,"sd":null},{"arm":"Total Non-switcher and Switcher","deltaMin":-3.3,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":5},"locations":{"siteCount":40,"countries":["United States"]},"refs":{"pmids":["20156032","20451686"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":17},"commonTop":["Hypertension","Bronchitis","Sinusitis","Arthralgia","Upper respiratory tract infection"]}}